Notes to the Company Financial Statements 1 Fixed asset investments Investments in subsidiaries Shares Loans Total $m $m $m At 1January 2018 15,996 15,486 31,482 Additions 2,974 2,974 Transfer to current assets 999 999 Capital reimbursement 16 16 Exchange 174 174 Amortisation 15 15 Impairment 38 38 At 31December 2018 15,942 17,302 33,244 A list of subsidiaries is included on pages 201 to 204.
2 Non-trade creditors 2018 2017 $m $m Amounts due within one year Short-term borrowings 211 199 Other creditors 165 119 Amounts owed to Group undertakings 7 7 383 325 3 Loans Repayment 2018 2017 dates $m $m Amounts due within one year Interest-bearing loans and borrowings unsecured Floating rate notes US dollars 2018 399 1.75% Callable bond US dollars 2018 998 1.95% Callable bond US dollars 2019 999 999 1,397 Amounts due after more than one year Amounts owed to Group undertakings unsecured 7.2% Loan US dollars 2023 283 283 Interest-bearing loans and borrowings unsecured 1.95% Callable bond US dollars 2019 999 2.375% Callable bond US dollars 2020 1,594 1,591 0.875% Non-callable bond euros 2021 854 890 0.25% Callable bond euros 2021 570 594 Floating rate note US dollars 2022 250 249 2.375% Callable bond US dollars 2022 994 992 3.5% Callable bond US dollars 2023 845 Floating rate note US dollars 2023 400 0.75% Callable bond euros 2024 1,022 1,067 3.375% Callable bond US dollars 2025 1,980 1,978 3.125% Callable bond US dollars 2027 743 742 1.25% Callable bond euros 2028 903 941 4% Callable bond US dollars 2029 992 5.75% Non-callable bond Pounds sterling 2031 443 468 6.45% Callable bond US dollars 2037 2,721 2,720 4% Callable bond US dollars 2042 987 987 4.375% Callable bond US dollars 2045 979 979 4.375% Callable bond US dollars 2048 736 Total amounts due after more than one year 17,296 15,480 Total loans 18,295 16,877 208 AstraZeneca Annual Report & Form 20-F Information 2018 Financial Statements Financial Statements 2018 2017 $m $m Loans are repayable: After five years from balance sheet date 11,506 10,165 From two to five years 4,196 4,316 From one to two years 1,594 999 Within one year 999 1,397 Total unsecured 18,295 16,877 With the exception of the 2018, 2022 and 2023 floating rate notes, all loans are at fixed interest rates.
Accordingly the fair values of the loans will change as market rates change.
However, since the loans are held at amortised cost, changes in interest rates and the credit rating of the Company do not have any effect on the Companys net assets.
IFRS 9 has been adopted from 1 January 2018.
The recoverability of all inter-company loans has been assessed in accordance with IFRS 9.
No impairment was identified and thus, no provision has been made.
The inter-company balances are considered to have low credit risk and the loss allowance is therefore limited to 12 month expected credit losses.
In 2018 there have been no credit losses.
4 Share capital Details of share capital movements in the year are included in Note 23 to the Group Financial Statements.
5 Contingent liabilities The Company is named as a party to legal proceedings in the Array BioPharma Inc. commercial litigation, which is described more fully in Note 29 to the Group Financial Statements.
Other The Company has guaranteed the external borrowing of a subsidiary in the amount of $286m 2017: $286m.
6 Statutory and other information The Directors were paid by another Group company in 2018 and 2017.
7 Subsequent events On 10 January 2019, the Company entered into a floating rate $500m committed bank loan agreement, which was drawn in full on 4 February 2019.
The loan is repayable in December 2019, although can be partially or fully paid in advance, but in that event, it is not available to be withdrawn.
AstraZeneca Annual Report & Form 20-F Information 2018 Notes to the Company Financial Statements 209
